Longboard pharmaceuticals provides corporate update and reports third quarter 2023 financial results

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended september 30, 2023. “we look forward to pacific study topline data in january 2024 evaluating lp352 in people living with developmental and epileptic encephalopathies, or dees. we are thrilled with t.
LBPH Ratings Summary
LBPH Quant Ranking